Summary: The placebo effect—where expectation of relief triggers measurable pain reduction—remains one of medicine’s most intriguing phenomena. A multi-institutional team led by researchers at the University of California San Diego has now mapped the precise brain circuitry that produces placebo-driven pain relief and identified where the brain releases its own opioid peptides to block pain.
By adapting a human placebo protocol for use in mice, the investigators traced a specific neural pathway from higher cortical regions down to the brainstem and spinal cord, and they located the site in the brain where endogenous opioids (endorphins) are released to produce analgesia.
Key Findings
- Broad-spectrum relief: Conditioning mice to expect relief from one kind of pain (for example, thermal pain) produced analgesia that generalized to other pain types, including injury-related inflammatory pain.
- Preemptive resilience: The findings suggest it may be possible to train people, ahead of an expected painful event such as surgery, to develop natural resistance to post-operative pain.
- An alternative to addictive opioids: Placebo analgesia recruits the brain’s own opioid system to deliver widespread pain relief without the addiction and adverse effects associated with external opioid medications.
- Translational validation: The study shows that mouse brain regions activated by placebo conditioning correspond to those implicated in human studies, supporting the use of rodent models to develop behavioral or “mental training” protocols for chronic pain management.
Source: UCSD
Placebo effects—where patients report symptom improvement despite receiving no active treatment—are increasingly recognized for their therapeutic potential in conditions such as pain and depression. However, the neural mechanisms that convert expectation into real physiological relief have been unclear.
A team led by Matthew Banghart, associate professor in the School of Biological Sciences at UC San Diego, pinpointed the circuit that enables placebo analgesia and demonstrated the essential role of endogenous opioid signaling at a specific brainsite known for pain modulation.
Published in the journal Neuron, the research uses a “reverse-translation” approach: a placebo protocol effective in humans was re-created in mice so that researchers could record and manipulate neural activity with cellular precision. Collaborating labs at the University of Pennsylvania and UC Irvine verified that the same brain regions implicated in human placebo responses show activity in the mouse model.
The investigators identified descending pathways that connect medial prefrontal and anterior cingulate cortical inputs to the ventrolateral periaqueductal gray (vlPAG) in the brainstem. Activity in these cortical-to-vlPAG circuits is necessary for placebo-induced analgesia, and descending vlPAG projections to the spinal cord are essential for both morphine and placebo pain relief.
Using novel opioid peptide sensors developed with partners at UC Davis and the Max Planck Florida Institute for Neuroscience, the team detected conditioning-enhanced release of endogenous opioid peptides in the vlPAG during placebo trials. To test causality, they applied a light-activated form of naloxone (PhNX) developed in Banghart’s lab to precisely block opioid signaling at targeted times and locations. Those manipulations showed that opioid signaling in the vlPAG is required for both morphine- and placebo-driven analgesia.
Co-first author Janie Chang-Weinberg noted that the experiments effectively trained mouse brains to produce their own localized, broad-spectrum painkillers on demand, avoiding off-target effects associated with systemic opioid drugs.
Importantly, placebo conditioning in pain-naive animals produced durable analgesia after later injury, indicating that conditioning can build lasting resilience against pain. This opens a pathway to translational strategies in which preventive placebo conditioning could be used to reduce reliance on opioid medications and improve pain outcomes for surgical patients and people living with chronic pain.
The authors emphasize that their results strengthen the translational relevance of rodent placebo models and lay groundwork for future experiments to refine conditioning protocols that might be applied clinically.
Key Questions Answered:
A: It begins with the brain, but it produces measurable biological effects. Expectation triggers release of endogenous opioids that act through brainstem circuits and descend to the spinal cord to suppress pain signaling. The process has clear physiological substrates, not merely imagination.
A: That is an intended long-term goal. If the brain can be conditioned to generate its own opioid-mediated analgesia reliably, such training could reduce dependence on synthetic opioids and their associated risks. Clinical translation will require carefully tested protocols and trials.
A: Conditioning pairs a consistent cue or treatment context with real pain relief. Over repeated pairings, the cue alone begins to elicit the brain’s pain-control response, leading to endogenous opioid release and reduced pain even without an active drug.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was provided by editorial staff.
About this pain and neurology research news
Author: Mario Aguilera
Source: UCSD
Contact: Mario Aguilera – UCSD
Image: The image is credited to Neuroscience News
Original Research: Open access. “Top-down control of the descending pain modulatory system drives multimodal placebo analgesia” by Giulia Livrizzi, Janie Chang-Weinberg, Desiree A. Johnson, Susan T. Lubejko, Jingzhu Liao, Blake A. Kimmey, Chunyang Dong, Yuan Li, Kevin T. Beier, Gregory Corder, Lin Tian, and Matthew R. Banghart. DOI: 10.1016/j.neuron.2026.03.025
Abstract
Top-down control of the descending pain modulatory system drives multimodal placebo analgesia
Placebo analgesia—where expectation and prior experience reduce pain following an inert treatment—is a strong clinical phenomenon whose causal neural basis has been uncertain. By reverse-translating a human placebo paradigm to mice, the authors identify cortical-to-brainstem circuits that causally mediate placebo pain relief. Conditioning suppresses both sensory and affective-motivational pain behaviors and generalizes to other, unconditioned forms of pain.
Descending neurons in the ventrolateral periaqueductal gray (vlPAG) are essential for both morphine and placebo analgesia, while placebo effects additionally require medial prefrontal and anterior cingulate cortical inputs to the vlPAG. Conditioning enhances noxious stimulus-evoked release of endogenous opioids in the vlPAG, which gates descending pain modulation. Notably, conditioning in pain-naive animals produces lasting placebo analgesia after injury.
These findings identify a central circuit mechanism for placebo analgesia and propose a translational strategy by which preventive placebo conditioning could build resilience to pain.